Malcolm Ranson

17.4k total citations · 4 hit papers
181 papers, 11.4k citations indexed

About

Malcolm Ranson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Malcolm Ranson has authored 181 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 78 papers in Pulmonary and Respiratory Medicine and 74 papers in Molecular Biology. Recurrent topics in Malcolm Ranson's work include Lung Cancer Treatments and Mutations (61 papers), Lung Cancer Research Studies (29 papers) and Cancer therapeutics and mechanisms (23 papers). Malcolm Ranson is often cited by papers focused on Lung Cancer Treatments and Mutations (61 papers), Lung Cancer Research Studies (29 papers) and Cancer therapeutics and mechanisms (23 papers). Malcolm Ranson collaborates with scholars based in United Kingdom, United States and Netherlands. Malcolm Ranson's co-authors include Caroline Dive, Fiona Blackhall, Andrew Hughes, Alastair Greystoke, Tim Ward, Helen Swaisland, Sarah Danson, Matthew Krebs, Glen Clack and Robert Szczepaniak‐Sloane and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Malcolm Ranson

177 papers receiving 11.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2015 1.6k citations Enriqueta Felip, Mireille Cantarini et al. profile →
Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer

2011 709 citations Matthew Krebs, Robert Szczepaniak‐Sloane et al. Journal of Clinical Oncology profile →
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 683 citations Malcolm Ranson, Hilary Calvert et al. Journal of Clinical Oncology profile →
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

2002 646 citations Malcolm Ranson, Helen Swaisland et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Malcolm Ranson	6.9k	4.9k	4.4k	2.4k	762	181	11.4k
Ramesh K. Ramanathan	10.2k 1.5×	4.0k 0.8×	3.9k 0.9×	2.3k 1.0×	722 0.9×	316	15.9k
Yasuhide Yamada	5.3k 0.8×	3.8k 0.8×	4.3k 1.0×	1.9k 0.8×	629 0.8×	308	10.9k
Kazuto Nishio	8.0k 1.2×	6.2k 1.3×	7.6k 1.7×	3.5k 1.5×	482 0.6×	532	16.2k
Stan B. Kaye	9.5k 1.4×	4.2k 0.8×	8.7k 2.0×	3.6k 1.5×	580 0.8×	217	19.2k
Ross C. Donehower	10.1k 1.5×	2.7k 0.6×	5.7k 1.3×	1.6k 0.7×	523 0.7×	223	16.0k
Anthony W. Tolcher	7.2k 1.0×	3.7k 0.8×	8.8k 2.0×	2.3k 1.0×	973 1.3×	438	16.5k
Jungsil Ro	7.9k 1.1×	5.3k 1.1×	3.5k 0.8×	3.6k 1.5×	412 0.5×	189	13.3k
Jeffrey G. Supko	7.6k 1.1×	7.3k 1.5×	7.4k 1.7×	2.9k 1.2×	391 0.5×	192	16.1k
Luka Milas	4.5k 0.7×	2.8k 0.6×	3.6k 0.8×	1.8k 0.8×	533 0.7×	201	9.9k
Brian Leyland‐Jones	11.6k 1.7×	3.3k 0.7×	5.7k 1.3×	4.6k 1.9×	676 0.9×	218	18.4k

Countries citing papers authored by Malcolm Ranson

Since Specialization

Citations

This map shows the geographic impact of Malcolm Ranson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Ranson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Ranson more than expected).

Fields of papers citing papers by Malcolm Ranson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm Ranson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Ranson. The network helps show where Malcolm Ranson may publish in the future.

Co-authorship network of co-authors of Malcolm Ranson

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm Ranson. A scholar is included among the top collaborators of Malcolm Ranson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm Ranson. Malcolm Ranson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Basu, Bristi, Emma Dean, M. Puglisi, et al.. (2015). First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. Clinical Cancer Research. 21(15). 3412–3419. 102 indexed citations

Donald, Emma, Gillian Ellison, Sarah R. Bujac, et al.. (2014). Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. Journal of Molecular Diagnostics. 16(3). 343–349. 38 indexed citations

Felip, Enriqueta, Malcolm Ranson, S. Cedrés, et al.. (2012). A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 13(6). 432–441. 16 indexed citations

Saleem, Azeem, Julian C. Matthews, Malcolm Ranson, et al.. (2011). Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients. Theranostics. 1. 290–301. 14 indexed citations

Hou, Jianmei, Matthew Krebs, Tim Ward, et al.. (2011). Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. American Journal Of Pathology. 178(3). 989–996. 343 indexed citations

Natale, Ronald B., David Bodkin, Ramaswamy Govindan, et al.. (2009). Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology. 27(15). 2523–2529. 194 indexed citations

Boss, David S., Gary K. Schwartz, Mark R. Middleton, et al.. (2009). Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Annals of Oncology. 21(4). 884–894. 50 indexed citations

Greystoke, Alastair, Kim Linton, Tim Illidge, et al.. (2008). Changes in serological biomarkers (BM) of cell death during chemotherapy (CT) in patients with lymphoma. Annals of Oncology. 19. 169–169. 1 indexed citations

Greystoke, Alastair, Jeffrey L. Cummings, Timothy H. Ward, et al.. (2008). Optimisation of circulating biomarkers of cell death for routine clinical use. Annals of Oncology. 19(5). 990–995. 65 indexed citations

10.

Ranson, Malcolm, Emma Dean, Tim Ward, et al.. (2007). Cell death ELISAs in the phase I clinical evaluation of AEG35156 (XIAP antisense) administered as an intravenous infusion over 7-days, 3-days, and 2-hours.. Molecular Cancer Therapeutics. 6.

11.

LaCasse, Eric C., Stephen Morris, Tim Ward, et al.. (2006). AEG35156, a XIAP antisense oligonucleotide, suppresses XIAP levels in targeted tissues isolated from pre-clinical models and from patients. Cancer Research. 66. 1142–1142. 3 indexed citations

12.

Jayson, Gordon C., C Mulatero, Malcolm Ranson, et al.. (2005). Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. European Journal of Cancer. 41(4). 555–563. 36 indexed citations

13.

Cummings, Jeffrey L., Timothy H. Ward, Eric C. LaCasse, et al.. (2005). Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. British Journal of Cancer. 92(3). 532–538. 64 indexed citations

14.

Ranson, Malcolm, et al.. (2004). Dual repair modulation reverses Temozolomide resistance in vitro. Molecular Cancer Therapeutics. 3(2). 123–127. 28 indexed citations

15.

Ranson, Malcolm & Suzanne E. Wardell. (2004). Gefitinib, a novel, orally administered agent for the treatment of cancer. Journal of Clinical Pharmacy and Therapeutics. 29(2). 95–103. 59 indexed citations

16.

Ranson, Malcolm & Mark X. Sliwkowski. (2002). Perspectives on Anti-HER Monoclonal Antibodies. Oncology. 63(Suppl. 1). 17–24. 57 indexed citations

17.

Ranson, Malcolm, T. Brian H. McMurry, Nicholas Thatcher, et al.. (2000). Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide.. Clinical Cancer Research. 6. 1 indexed citations

18.

Anderson, Heather, J.H. Scarffe, Malcolm Ranson, et al.. (1995). VAD chemotherapy as remission induction for multiple myeloma. British Journal of Cancer. 71(2). 326–330. 69 indexed citations

19.

Fentiman, IS, Anthony Howell, Siow Ming Lee, et al.. (1994). A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. British Journal of Cancer. 70(4). 729–731. 8 indexed citations

20.

Narayanan, Manikandan, G.R. Morgenstern, James Chang, et al.. (1994). Acute lymphoblastic leukaemia following Hodgkin's disease is associated with a good prognosis. British Journal of Haematology. 86(4). 867–869. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact